Navigation Links
CoreLab Partners, Medical Image Assessment Experts, Announces Its Entry Into the Early Alzheimer's Imaging Market Space
Date:12/6/2012

PRINCETON, N.J., Dec. 6, 2012 /PRNewswire/ -- CoreLab Partners, Inc., a leading independent core lab providing centralized cardiac safety services and medical imaging assessment, has launched new imaging capabilities targeted at the utilization of independent central image review in the detection of early Alzheimer's disease.

"Recognizing the ongoing evolution of magnetic resonance imaging (MRI), positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging in dementia-related clinical trials, CoreLab Partners has put into place a team of knowledgeable experts combined with advanced technological tools to ensure current and emerging image assessment needs are met," stated Dr. Michael Woehler, President & CEO. "This exciting new capability is a natural extension of our industry-leading suite of imaging science solutions and marks a significant milestone in the utilization of scientifically validated tools designed to accurately quantify brain structure volumetric data," added Woehler.

Senior members of the CoreLab Partners' medical affairs team will be attending CBIs upcoming 6th Annual Alzheimer's Drug Development Summit to be held in Philadelphia, PA from December 11 – 12, 2012; please join us for this important industry event as the scientific community shares their future perspectives from the Dominantly Inherited Alzheimer's Network (DIAN).

About CoreLab Partners, Inc.

CoreLab Partners, with offices in North America, Europe and Asia, provides comprehensive medical image assessment and cardiac safety services to the pharmaceutical, biotechnology and medical device industries.  An efficient operational process facilitates successful new drug development programs by employing an experienced clinical operations team combined with board certified, sub-specialty trained Radiologists, Cardiologists, nuclear medicine physicians and Oncologists. CoreLab Partners delivers disciplined solutions for the collection, analysis and management of patient images and cardiac safety & efficacy information during drug development. Driven by best-in-class science, emerging technologies and service quality, CoreLabs is a global leader providing imaging sciences in all major modalities complemented by service offerings in the conduct of automated ECG, Thorough QT, Holter Monitoring, Ambulatory Blood Pressure Monitoring and Pulse Wave Analysis.

http://www.corelabpartners.com

Contact:

Daja Herald
Marketing Manager
Email: dherald@corelabpartners.com
Phone: 609-936-2600

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE CoreLab Partners, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. CoreLab Partners Opens Office in Tokyo, Japan
2. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
3. DiaTech Life Sciences Announces Medical Advisory Board
4. Van Andel Institute Partners with UNCF to Recruit Students to Biomedical Research Careers
5. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
6. China Sky One Medical to Jointly Launch Adult Stem Cell Research Enterprise
7. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
8. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
9. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
10. Live Press Briefing on Findings of Biomedical Industry CEO Survey
11. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... A ... in Hong Kong. , Nerium International is proud to introduce its Age-Defying Night ... Cream, NeriumAD™ Formula to consumers across Hong Kong. The luxury skincare products contain ...
(Date:2/17/2017)... 2017 According to a ... (Consumables, Service), Type (Safety, Efficacy, Validation), Disease Indication ... and Development, Disease-Risk) - Global Forecast to 2021" ... reach USD 53.34 Billion by 2021 from USD ... of 13.8% during the forecast period (2016-2021). ...
(Date:2/17/2017)... 2017  If only one in every hundred ... resistance to chemotherapy, thousands of cancer cells would ... on finding these mutations in ever-smaller subpopulations of ... DNA in blood — to guide treatment decisions ... Unfortunately, however, detecting these genetic anomalies may be ...
(Date:2/17/2017)...  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today presented ... drug candidates, PTG-100 and PTG-200, at the 12 ... Colitis Organization (ECCO).  The ECCO congress is being ... from February 15 – 18, 2017. ... drug candidates PTG-100 and PTG-200. PTG-100, a potential ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... NEW YORK , Feb. 8, 2017 /PRNewswire/ ... an individual,s voice to match it against a ... voice such as pitch, cadence, and tone are ... systems require minimal hardware installation, as most PCs ... remotely for different transactions. Voice recognition biometrics are ...
Breaking Biology News(10 mins):